REVB
MaterialsRevelation Biosciences Inc
Live · NASDAQ · May 9, Close
What's Moving REVB Today?
No stock-specific AI insight has been generated for REVB yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
REVB News
20 articles- REVB Poised for Big YearYahoo Finance·May 8, 2026
- Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026Yahoo Finance·May 7, 2026
- Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory BoardYahoo Finance·Apr 6, 2026
- Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical StudyYahoo Finance·Mar 30, 2026
- REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth ConferenceYahoo Finance·Mar 24, 2026
- Revelation Biosciences to Host Fireside Chat at 38th Annual Roth ConferenceYahoo Finance·Mar 19, 2026
- REVB 2026 Starts in Positive FashionYahoo Finance·Feb 27, 2026
- Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025Yahoo Finance·Feb 26, 2026
- REVB Comes to Agreement with FDAYahoo Finance·Jan 29, 2026
- Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026Yahoo Finance·Jan 26, 2026
- Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross ProceedsYahoo Finance·Jan 23, 2026
- BC-Most Active StocksYahoo Finance·Jan 23, 2026
- Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKIYahoo Finance·Jan 21, 2026
- REVB: 2026 Shaping Up to be Great YearYahoo Finance·Jan 16, 2026
- Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)Yahoo Finance·Jan 14, 2026
- Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·Jan 12, 2026
- Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical DevelopmentYahoo Finance·Jan 7, 2026
- Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special MeetingYahoo Finance·Dec 1, 2025
- Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This YearYahoo Finance·Nov 20, 2025
- REVB Ready to Advance Groundbreaking TreatmentYahoo Finance·Nov 7, 2025
All 20 articles loaded
Price Data
Fundamentals
Trading
About Revelation Biosciences Inc
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.